Peripheral Synergistic Interaction Between Lidocaine and Lumiracoxib on the 1% Formalin Test in Rats

Q3 Medicine
M. Ortiz, G. Castañeda-Hernández, J. Izquierdo-Vega, H. Ponce-Monter
{"title":"Peripheral Synergistic Interaction Between Lidocaine and Lumiracoxib on the 1% Formalin Test in Rats","authors":"M. Ortiz, G. Castañeda-Hernández, J. Izquierdo-Vega, H. Ponce-Monter","doi":"10.2174/1876386301104010008","DOIUrl":null,"url":null,"abstract":"It has been shown that the association of non-steroidal anti-inflammatory drugs (NSAIDs) with analgesic agents can increase their antinociceptive activity, allowing the use of lower doses and thus limiting side effects. Therefore, the aim of the present study was to examine the possible pharmacological interaction between lumiracoxib and lidocaine at the local peripheral level in the rat using the 1% formalin test and isobolographic analysis. Lumiracoxib, lidocaine or fixed-dose ratio (1:1) lumiracoxib-lidocaine combinations were administered locally in the formalin-injured paw and the antinociceptive effect was evaluated. All treatments produced a dose-dependent antinociceptive effect. ED40 values were estimated for the individual drugs and an isobologram was constructed. The derived theoretical ED40 for the lumiracoxib- lidocaine combination was 599.3 ± 58.8 � g/paw, being significantly higher than the actually observed experimental ED40 value, 393.6 ± 39.7 � g/paw. This result correspond to a synergistic interaction between lumiracoxib and lidocaine at the local peripheral level, potency being about one and half times higher with regard to that expected from the addition of the effects of the individual drugs. Data suggest that low doses of the lumiracoxib-lidocaine combination can interact synergistically at the peripheral level and therefore this drug association may represent a therapeutic advantage for the clinical treatment of procedural or inflammatory pain.","PeriodicalId":53614,"journal":{"name":"Open Pain Journal","volume":"4 1","pages":"8-14"},"PeriodicalIF":0.0000,"publicationDate":"2011-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Pain Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1876386301104010008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

It has been shown that the association of non-steroidal anti-inflammatory drugs (NSAIDs) with analgesic agents can increase their antinociceptive activity, allowing the use of lower doses and thus limiting side effects. Therefore, the aim of the present study was to examine the possible pharmacological interaction between lumiracoxib and lidocaine at the local peripheral level in the rat using the 1% formalin test and isobolographic analysis. Lumiracoxib, lidocaine or fixed-dose ratio (1:1) lumiracoxib-lidocaine combinations were administered locally in the formalin-injured paw and the antinociceptive effect was evaluated. All treatments produced a dose-dependent antinociceptive effect. ED40 values were estimated for the individual drugs and an isobologram was constructed. The derived theoretical ED40 for the lumiracoxib- lidocaine combination was 599.3 ± 58.8 � g/paw, being significantly higher than the actually observed experimental ED40 value, 393.6 ± 39.7 � g/paw. This result correspond to a synergistic interaction between lumiracoxib and lidocaine at the local peripheral level, potency being about one and half times higher with regard to that expected from the addition of the effects of the individual drugs. Data suggest that low doses of the lumiracoxib-lidocaine combination can interact synergistically at the peripheral level and therefore this drug association may represent a therapeutic advantage for the clinical treatment of procedural or inflammatory pain.
利多卡因和鲁米拉昔布对1%福尔马林大鼠外周协同作用的影响
研究表明,非甾体抗炎药(NSAIDs)与镇痛药联合使用可增加其抗痛觉活性,从而允许使用较低剂量,从而限制副作用。因此,本研究的目的是通过1%福尔马林试验和等密度分析,在大鼠的局部外周水平上检查lumiracoxib和利多卡因之间可能的药理相互作用。在福尔马林损伤足部局部给予鲁米拉昔布、利多卡因或固定剂量比(1:1)鲁米拉昔布-利多卡因联合用药,观察其抗伤害性效果。所有的治疗都产生了剂量依赖性的抗感知效果。估计了每种药物的ED40值,并构建了等温图。lumiracoxib-利多卡因联合用药的理论ED40值为599.3±58.8 μ g/paw,明显高于实际观察到的实验ED40值393.6±39.7 μ g/paw。这一结果对应于lumiracoxib和利多卡因在局部外周水平上的协同相互作用,效力比预期的单个药物的作用高1.5倍。数据显示,低剂量的lumiracoxib-利多卡因组合可以在外周水平上协同作用,因此这种药物关联可能代表了临床治疗程序性或炎症性疼痛的治疗优势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Open Pain Journal
Open Pain Journal Medicine-Anesthesiology and Pain Medicine
CiteScore
0.80
自引率
0.00%
发文量
9
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信